Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 9, 2015, Pages 2042-2047

  Croyal, Mikaël ^a,b   Ouguerram, Khadija ^a,b   Passard, Maxime ^a,b   Ferchaud Roucher, Véronique ^a,b   Chétiveaux, Maud ^a   Billon Crossouard, Stéphanie ^a,b   De Gouville, Anne Charlotte ^c   Lambert, Gilles ^a,b   Krempf, Michel ^a,b,d   Nobécourt, Estelle ^a,d  

^a UNIVERSITÉ DE NANTES   (France)

^b HÔTEL DIEU   (France)

^c GLAXOSMITHKLINE   (France)

^d CHU de Nantes   (France)

Author keywords

apolipoprotein (a); hypertriglyceridemia; kinetics; lipoprotein (a); niacin

Indexed keywords

3 HYDROXYLEUCINE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B100; EXTENDED RELEASE NICOTINIC ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; DELAYED RELEASE FORMULATION; NICOTINIC ACID;

ADULT; ARTICLE; BODY MASS; CHRONOTHERAPY; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DELAYED RELEASE FORMULATION; DOSE RESPONSE;

APOPROTEIN(A); CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NIACIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84940392460     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305835     Document Type: Article

References (35)

1. Kronenberg F, Utermann G, Lipoprotein(a): resurrected by genetics. J Intern Med 2013 273 6 30. doi: 10.1111/j.1365-2796.2012.02592.x
2. Utermann G, Weber W, Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett 1983 154 357 361
3. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr, The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994 93 2758 2763. doi: 10.1172/JCI117292
4. Nordestgaard BG, Chapman MJ, Ray K, European Atherosclerosis Society Consensus Panel Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010 31 2844 2853. doi: 10.1093/eurheartj/ehq386
5. Clarke R, Peden JF, Hopewell JC, PROCARDIS Consortium Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009 361 2518 2528. doi: 10.1056/NEJMoa0902604
6. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG, Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009 301 2331 2339. doi: 10.1001/jama.2009.801
7. NACB LMPG Committee Members, Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson PW. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009;55:378-384
8. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P, Determining the Efficacy and Tolerability Investigators Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010 363 2406 2415. doi: 10.1056/NEJMoa1009744
9. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010 375 998 1006. doi: 10.1016/S0140-6736(10)60284-X
10. Sahebkar A, Watts GF, New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther 2013 27 559 567. doi: 10.1007/s10557-013-6479-4
11. McConnell JP, Guadagno PA, Dayspring TD, Hoefner DM, Thiselton DL, Warnick GR, Harris WS, Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol 2014 8 550 553. doi: 10.1016/j.jacl.2014.08.003
12. Carlson LA, Nicotinic acid: the broad-spectrum lipid drug A 50th anniversary review. J Intern Med 2005 258 94 114. doi: 10.1111/j.1365-2796.2005.01528.x
13. Chennamsetty I, Kostner KM, Claudel T, Vinod M, Frank S, Weiss TS, Trauner M, Kostner GM, Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res 2012 53 2405 2412. doi: 10.1194/jlr.M029769
14. Lamon-Fava S, Diffenderfer MR, Marcovina SM, Lipoprotein(a) metabolism. Curr Opin Lipidol 2014 25 189 193. doi: 10.1097/MOL.0000000000000070
15. Pan Y, Zhou H, Mahsut A, Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS. J Lipid Res 2014 55 1179 1187. doi: 10.1194/jlr.D047829
16. Zhou H, Castro-Perez J, Lassman ME, Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun Mass Spectrom 2013 27 1294 1302. doi: 10.1002/rcm.6572
17. Lassman ME, McLaughlin TM, Zhou H, Pan Y, Marcovina SM, Laterza O, Roddy TP, Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2014 28 1101 1106. doi: 10.1002/rcm.6883
18. Ouguerram K, Magot T, Zaïr Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M, Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther 2003 306 332 337. doi: 10.1124/jpet.103.048991
19. Foster DM, Barrett PH, Toffolo G, Beltz WF, Cobelli C, Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res 1993 34 2193 2205
20. Frischmann ME, Ikewaki K, Trenkwalder E, Lamina C, Dieplinger B, Soufi M, Schweer H, Schaefer JR, König P, Kronenberg F, Dieplinger H, In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis 2012 225 322 327. doi: 10.1016/j.atherosclerosis.2012.09.031
21. Kamanna VS, Kashyap ML, Mechanism of action of niacin. Am J Cardiol 2008 101 8A 20B 26B. doi: 10.1016/j.amjcard.2008.02.029
22. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Nyaku M, Horvath KV, Asztalos BF, Otokozawa S, Ai M, Matthan NR, Lichtenstein AH, Dolnikowski GG, Schaefer EJ, Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008 28 1672 1678. doi: 10.1161/ATVBAHA.108.164541
23. Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S, Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010 95 2727 2735. doi: 10.1210/jc.2009-2622
24. Niemeier A, Willnow T, Dieplinger H, Jacobsen C, Meyer N, Hilpert J, Beisiegel U, Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler Thromb Vasc Biol 1999 19 552 561
25. Kronenberg F, Utermann G, Dieplinger H, Lipoprotein(a) in renal disease. Am J Kidney Dis 1996 27 1 25
26. Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K, Dieplinger H, In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007 71 1036 1043. doi: 10.1038/sj.ki.5002131
27. Kalil RS, Wang JH, de Boer IH, Mathew RO, Ix JH, Asif A, Shi X, Boden WE, Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int 2015. doi: 10.1038/ki.2014.383
28. Yang XP, Amar MJ, Vaisman B, Bocharov AV, Vishnyakova TG, Freeman LA, Kurlander RJ, Patterson AP, Becker LC, Remaley AT, Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res 2013 54 2450 2457. doi: 10.1194/jlr.M038877
29. Romagnuolo R, Scipione C, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015 290 11649 11662. doi: 10.1074/jbc.M114.611988
30. Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ, Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol 2015 115 178 182. doi: 10.1016/j.amjcard.2014.10.018
31. Vergès B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B, Lack of association between plasma PCSK9 and LDL-ApoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis 2011 219 342 348. doi: 10.1016/j.atherosclerosis.2011.07.098
32. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011 365 2255 2267. doi: 10.1056/NEJMoa1107579
33. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J, HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014 371 203 212. doi: 10.1056/NEJMoa1300955
34. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013 34 1279 1291
35. Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM, Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013 62 1575 1579. doi: 10.1016/j.jacc.2013.06.051